Persson S
Department of Cardiology, University Hospital, Lund, Sweden.
Drugs. 1991;42 Suppl 2:54-60. doi: 10.2165/00003495-199100422-00009.
A reliable theoretical background exists to support a secondary preventive effect of calcium antagonists after myocardial infarction. Recent studies also indicate that positive results can be achieved with diltiazem and, in particular, verapamil, provided that they are not given to patients suffering clinically manifest myocardial failure during the acute phase of the disease. When the results of treatment with verapamil and diltiazem are compared with comparable studies with beta-blockers, there is no convincing difference as to their effect on a reduction in mortality. However, studies on nifedipine have shown a negative trend, indicating that the calcium channel blockers should not be regarded as one entity in this respect.
有可靠的理论背景支持钙拮抗剂在心肌梗死后的二级预防作用。近期研究还表明,地尔硫䓬,尤其是维拉帕米,可取得阳性结果,但前提是在疾病急性期不给有临床明显心力衰竭的患者使用。当将维拉帕米和地尔硫䓬的治疗结果与β受体阻滞剂的类似研究进行比较时,就降低死亡率的效果而言,没有令人信服的差异。然而,硝苯地平的研究显示出负面趋势,表明在这方面钙通道阻滞剂不应被视为一个整体。